Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BI 474121 in Healthy Males
NCT04672954Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 474121 in schizophrenia (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Exposure-related Change From Baseline (Calculated as Ratio) of Cyclic Guanosine Monophosphate (cGMP) in Cerebrospinal Fluid (CSF) up to 24 hours and Maximum Measured Concentration (Cmax) Ratio of BI 474121 in Cerebrospinal Fluid (CSF) Compared to Plasma up to 72 hours. Started Jan 2021; status: completed.
02
Drugs
BI 474121
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04672954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672954.